Briacell Therapeutics Corp falls sharply amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 Dec 25
Source: FWP
Briacell Therapeutics Corp's stock price dropped by 20.66%, crossing below the 5-day SMA, indicating a significant decline in value.
This decline occurs despite the broader market strength, with the Nasdaq-100 up 0.32% and the S&P 500 up 0.34%. The movement suggests sector rotation as investors may be reallocating their investments away from biotech stocks like Briacell.
The implications of this price movement could indicate a shift in investor sentiment towards other sectors, potentially impacting Briacell's future performance as it navigates through this challenging market environment.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





